Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis

References

• Noseworthy JH Lucchinetti C Rodriguez M Weinshenker BG Multiple sclerosis N Engl J Med 2000 343 13 938 952 11006371
   PubMed Web of Science ®Google Scholar
• Perumal J Khan O Emerging disease-modifying therapies in multiple sclerosis Curr Treat Options Neurol 2012 14 3 256 263 22426573
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS Neurology 2001 56 12 1628 1636 11425926
   PubMed Web of Science ®Google Scholar
• Paty DW Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 1993 43 4 662 667 8469319
   PubMed Web of Science ®Google Scholar
• Simon JH Jacobs LD Campion M Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group Ann Neurol 1998 43 1 79 87 9450771
   PubMed Web of Science ®Google Scholar
• Comi G Filippi M Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group Ann Neurol 2001 49 3 290 297 11261502
   PubMed Web of Science ®Google Scholar
• Polman CH O’Connor PW Havrdova E AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 2006 354 9 899 910 16510744
   PubMed Web of Science ®Google Scholar
• Rudick RA Stuart WH Calabresi PA SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 2006 354 9 911 923 16510745
   PubMed Web of Science ®Google Scholar
• Hartung HP Gonsette R König N Mitoxantrone in Multiple Sclerosis Study Group (MIMS) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 2002 360 9350 2018 2025 12504397
   PubMed Web of Science ®Google Scholar
• Cohen JA Barkhof F Comi G TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 2010 362 5 402 415 20089954
   PubMed Web of Science ®Google Scholar
• Kappos L Radue EW O’Connor P FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 2010 362 5 387 401 20089952
   PubMed Web of Science ®Google Scholar
• O’Connor P Wolinsky JS Confavreux C TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 2011 365 14 1293 1303 21991951
   PubMed Web of Science ®Google Scholar
• Miller A Kappos L Comi Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second, pivotal, phase 3 placebo-controlled study (S01.004) [abstract] Neurology 2013 80 Meeting Abstracts 1 S01.004
   Google Scholar
• Gold R Kappos L Arnold DL DEFINE Study Investigators Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 2012 367 12 1098 1107 22992073
   PubMed Web of Science ®Google Scholar
• Fox RJ Miller DH Phillips JT CONFIRM Study Investigators Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 2012 367 12 1087 1097 22992072
   PubMed Web of Science ®Google Scholar
• Comi G Jeffery D Kappos L ALLEGRO Study Group Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 2012 366 11 1000 1009 22417253
   PubMed Web of Science ®Google Scholar
• Vollmer TL Soelburg P Arnold DL BRAVO Study Group [abstract] ECTRIMS 2011 abstract 143
   Google Scholar
• Cannella B Raine CS The adhesion molecule and cytokine profile of multiple sclerosis lesions Ann Neurol 1995 37 4 424 435 7536402
   PubMed Web of Science ®Google Scholar
• Yednock TA Cannon C Fritz LC Sanchez-Madrid F Steinman L Karin N Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 1992 356 6364 63 66 1538783
   PubMed Web of Science ®Google Scholar
• Hauser SL Waubant E Arnold DL HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 2008 358 7 676 688 18272891
   PubMed Web of Science ®Google Scholar
• Cohen JA Coles AJ Arnold DL CARE-MS I investigators Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 2012 380 9856 1819 1828 23122652
   PubMed Web of Science ®Google Scholar
• Coles AJ Twyman CL Arnold DL CARE-MS II investigators Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 2012 380 9856 1829 1839 23122650
   PubMed Web of Science ®Google Scholar
• Vincenti F Kirkman R Light S Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N Engl J Med 1998 338 3 161 165 9428817
   PubMed Web of Science ®Google Scholar
• Adu D Cockwell P Ives NJ Shaw J Wheatley K Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials BMJ 2003 326 7393 789 12689974
   PubMed Web of Science ®Google Scholar
• Waldmann TA The IL-2/IL-15 receptor systems: targets for immunotherapy J Clin Immunol 2002 22 2 51 56 11998892
   PubMed Web of Science ®Google Scholar
• Bielekova B Richert N Howard T Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta Proc Natl Acad Sci U S A 2004 101 23 8705 8708 15161974
   PubMed Web of Science ®Google Scholar
• Goebel J Stevens E Forrest K Roszman TL Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events Transpl Immunol 2000 8 3 153 159 11147695
   PubMed Web of Science ®Google Scholar
• Waldmann TA O’Shea J The use of antibodies against the IL-2 receptor in transplantation Curr Opin Immunol 1998 10 5 507 512 9794841
   PubMed Web of Science ®Google Scholar
• Nelson BH Willerford DM Biology of the interleukin-2 receptor Adv Immunol 1998 70 1 81 9755337
   PubMed Web of Science ®Google Scholar
• Queen C Schneider WP Selick HE A humanized antibody that binds to the interleukin 2 receptor Proc Natl Acad Sci U S A 1989 86 24 10029 10033 2513570
   PubMed Web of Science ®Google Scholar
• Depper JM Leonard WJ Robb RJ Waldmann TA Greene WC Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation J Immunol 1983 131 2 690 696 6408186
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M Fromont C Le Deist F Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin Transplantation 1990 50 1 1 7 2142343
   PubMed Web of Science ®Google Scholar
• Bielekova B Catalfamo M Reichert-Scrivner S Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis Proc Natl Acad Sci U S A 2006 103 15 5941 5946 16585503
   PubMed Web of Science ®Google Scholar
• Kalia V Sarkar S Subramaniam S Haining WN Smith KA Ahmed R Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo Immunity 2010 32 1 91 103 20096608
   PubMed Web of Science ®Google Scholar
• Bielekova B Daclizumab therapy for multiple sclerosis Neurotherapeutics 2013 10 1 55 67 23055048
   PubMed Web of Science ®Google Scholar
• Bielekova B Howard T Packer AN Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis Arch Neurol 2009 66 4 483 489 19364933
   PubMed Web of Science ®Google Scholar
• Guleria I Sayegh MH Maternal acceptance of the fetus: true human tolerance J Immunol 2007 178 6 3345 3351 17339426
   PubMed Web of Science ®Google Scholar
• Jacobs R Hintzen G Kemper A CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells Eur J Immunol 2001 31 10 3121 3127 11592089
   PubMed Web of Science ®Google Scholar
• Airas L Saraste M Rinta S Elovaara I Huang YH Wiendl H Finnish Multiple Sclerosis and Pregnancy Study Group Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells Clin Exp Immunol 2008 151 2 235 243 18062798
   PubMed Web of Science ®Google Scholar
• Jiang W Chai NR Maric D Bielekova B Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis J Immunol 2011 187 2 781 790 21666061
   PubMed Web of Science ®Google Scholar
• Wuest SC Edwan JH Martin JF A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy Nat Med 2011 17 5 604 609 21532597
   PubMed Web of Science ®Google Scholar
• Granucci F Vizzardelli C Pavelka N Inducible IL-2 production by dendritic cells revealed by global gene expression analysis Nat Immunol 2001 2 9 882 888 11526406
   PubMed Web of Science ®Google Scholar
• Perry JS Han S Xu Q Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis Sci Transl Med 2012 4 145 145ra106
   PubMed Web of Science ®Google Scholar
• Withers DR Gaspal FM Mackley EC Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissue J Immunol 2012 189 5 2094 2098 22855716
   PubMed Web of Science ®Google Scholar
• Rose JW Burns JB Bjorklund J Klein J Watt HE Carlson NG Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results Neurology 2007 69 8 785 789 17709711
   PubMed Web of Science ®Google Scholar
• Ali EN Healy BC Stazzone LA Brown BA Weiner HL Khoury SJ Daclizumab in treatment of multiple sclerosis patients Mult Scler 2009 15 2 272 274 19136546
   PubMed Web of Science ®Google Scholar
• Wynn D Kaufman M Montalban X CHOICE investigators Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurol 2010 9 4 381 390 20163990
   PubMed Web of Science ®Google Scholar
• Gold R Giovannoni G Selmaj K SELECT study investigators Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial Lancet 2013 381 9884 2167 2175 23562009
   PubMed Web of Science ®Google Scholar
• Biogen Idec Safety and efficacy extension study of daclizumab high yield process (DAC HYP) in subjects with multiple sclerosis who have completed study 205MS201 (NCT00390221) to treat relapsing-remitting multiple sclerosis. (SELECTION) Available from: http://clinicaltrials.gov/ct2/show/NCT00870740?term=NCT00390221&rank=2. NLM identifier: NCT00870740Accessed September 11, 2013
   Google Scholar
• Giovannoni G Gold R Selmaj K Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis October 10–13, 2012 Lyon, France Abstract P169
   Google Scholar
• Ohayon J Oh U Richert N CNS vasculitis in a patient with MS on daclizumab monotherapy Neurology 2013 80 5 453 457 23303850
   PubMed Web of Science ®Google Scholar
• Biogen Idec Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis (DECIDE) Available from: http://clinicaltrials.gov/ct2/show/NCT01064401. NLM identifier: NCT01064401Accessed August 26, 2013
   Google Scholar